1型神经纤维瘤病中异常信号强化灶的纵向评估
回顾19例1型神经纤维瘤病连续患者的109个MRI数据集,纵向分析23个初诊为异常信号灶的强化实质病灶,平均随访6.5年;病灶可随时间缩小或完全消退,胼胝体压部病灶平均12.2岁开始缩小,后颅窝病灶17.1岁,其他部位9.4岁。
要点
- 1型神经纤维瘤病患者的强化异常信号灶虽罕见,但可随时间自行缩小或完全消退。
- 胼胝体压部病灶平均峰值体积295 mm³,10个中5个缩小、3个完全消退。
- 出现非典型特征时应进一步评估以排查潜在肿瘤。
关键影像表现/征象
- 23个病灶分布:胼胝体压部10个、胼胝体体部1个、额叶白质2个、苍白球3个、小脑6个、中脑1个。
- 胼胝体压部病灶平均峰值体积295 mm³,10个中5个缩小、3个完全消退、2个因影像表现变化行手术干预后证实为神经节细胞瘤和WHO II级星形细胞瘤。
- 胼胝体体部病灶平均峰值体积44 mm³且缩小;额叶白质病灶平均峰值体积32 mm³,2个中1个完全消退。
- 苍白球病灶平均峰值体积50 mm³且全部完全消退;小脑病灶平均峰值体积206 mm³,6个中3个缩小、1个完全消退;中脑病灶平均峰值体积34 mm³。
诊断标准与关键数值
- 胼胝体压部病灶平均于12.2岁开始缩小,后颅窝病灶于17.1岁,其他部位于9.4岁。
临床应用与阅片要点
- 对1型神经纤维瘤病患者的强化异常信号灶进行随访MRI有助于确认其消退。
- 出现非典型特征时应进一步评估以排查潜在肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Patients with neurofibromatosis 1 are at increased risk of developing brain tumors, and differentiation from contrast-enhancing foci of abnormal signal intensity can be challenging. We aimed to longitudinally characterize rare, enhancing foci of abnormal signal intensity based on location and demographics.
MATERIALS AND METHODS: A total of 109 MR imaging datasets from 19 consecutive patients (7 male; mean age, 8.6 years; range, 2.3-16.8 years) with neurofibromatosis 1 and a total of 23 contrast-enhancing parenchymal lesions initially classified as foci of abnormal signal intensity were included. The mean follow-up period was 6.5 years (range, 1-13.8 years). Enhancing foci of abnormal signal intensity were followed up with respect to presence, location, and volume. Linear regression analysis was performed.
RESULTS: Location, mean peak volume, and decrease in enhancing volume over time of the 23 lesions were as follows: 10 splenium of the corpus callosum (295 mm3, 5 decreasing, 3 completely resolving, 2 surgical intervention for change in imaging appearance later confirmed to be gangliocytoma and astrocytoma WHO II), 1 body of the corpus callosum (44 mm3, decreasing), 2 frontal lobe white matter (32 mm3, 1 completely resolving), 3 globus pallidus (50 mm3, all completely resolving), 6 cerebellum (206 mm3, 3 decreasing, 1 completely resolving), and 1 midbrain (34 mm3). On average, splenium lesions began to decrease in size at 12.2 years, posterior fossa lesions at 17.1 years, and other locations at 9.4 years of age.
CONCLUSIONS: Albeit very rare, contrast-enhancing lesions in patients with neurofibromatosis 1 may regress over time. Follow-up MR imaging aids in ascertaining regression. The development of atypical features should prompt further evaluation for underlying tumors.
引用
- Hainc N, Wagner MW, Laughlin S, et al. Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. AJNR Am J Neuroradiol. 2021. PMID: 33541905. doi:10.3174/ajnr.A6974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。